ASH 2018: Highlights on DRd in newly diagnosed multiple myeloma patients (MAIA trial)

Speaker: Thierry Facon

Reporting from ASH 2018, Thierry Facon explains that the MAIA trial explored triplet therapy in elderly patients with newly diagnosed multiple myeloma ineligible for transplant. The study met its primary endpoint, showing 15% difference in progression-free survival rate at 30 months. The response rate was also better in the daratumumab arm with a better quality of response as 24% of patients achieve MRD negative status. The safety profile was comparable with what has been observed in other daratumumab trials. This combination should become the new standard of care in this group of patients.

ASH 2018 abstract:

LBA-2 Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA) ; Thierry Facon